European Society for Medical Oncology Targeted Anticancer Therapies Congress 2023
Format: 78 videos + 56 pdfs, size: 7.39 GB
Course Audience: oncologist
Overview:
- Start date 06 Mar 2023
- End date 08 Mar 2023
- Location Paris, France
ESMO Targeted Anticancer Therapies Congress 2023 took place on 6-8 March 2023 in Paris, France
ESMO TAT, known as “The Home of Phase I in Oncology”, is the leading congress focusing on promising new anticancer targets and agents, with a particular emphasis on those in early phase clinical development.
This congress was dedicated to improving the conduct of early anti-cancer clinical trials, bringing together those who are developing the most promising new cancer drugs and unveiling exciting new data.
With a record-breaking number of abstracts submitted, this edition offered a unique opportunity for stakeholders from academia and industry to discuss with clinicians, researchers, and regulators the global dissemination of knowledge and clinical research expertise in the field of innovative cancer therapeutics, to the benefit of cancer patients worldwide.
The ESMO Targeted Anticancer Therapies Congress 2023, is the premier international meeting focusing on promising new anticancer targets and agents, with a particular focus on those in early phase clinical development.
+ Topics:
Brain penetrance of drugs Chemical aspects of developing brain penetrant agents (Video MP4 Format)
Brain penetrance of drugs Chemical aspects of developing brain penetrant agents (PDF Format)
Brain penetrance of drugs Immunotherapy for brain cancer Reimagining the pharmacological audit trail for drug delivery for brain tumours (Video MP4 Format)
Brain penetrance of drugs Immunotherapy for brain cancer Reimagining the pharmacological audit trail for drug delivery for brain tumours (PDF Format)
Brain penetrance of drugs Q&A (Video MP4 Format)
Cell therapy Biomarkers for toxicities in cell therapy (Video MP4 Format)
Cell therapy Biomarkers for toxicities in cell therapy (PDF Format)
Cell therapy Mechanisms of resistance in CAR-T (Video MP4 Format)
Cell therapy Mechanisms of resistance in CAR-T (PDF Format)
Cell therapy Neoantigen specific TIL for solid tumours (Video MP4 Format)
Cell therapy Neoantigen specific TIL for solid tumours (PDF Format)
Cell therapy Q&A (Video MP4 Format)
final_programme_tat2023 (PDF Format)
Keynote address Introduction to the Keynote lecture (Video MP4 Format)
Keynote address Novel insights in mutational signatures uncovered through whole genome sequencing of cancer and experimental models (Video MP4 Format)
Keynote address Novel insights in mutational signatures uncovered through whole genome sequencing of cancer and experimental models (PDF Format)
Mini Oral session 28MO – Adapting the Time-to-Event Continual Reassessment Method (TiTE-CRM) to include consolidation (Video MP4 Format)
Mini Oral session 28MO – Adapting the Time-to-Event Continual Reassessment Method (TiTE-CRM) to include consolidation (PDF Format)
Mini Oral session 70MO – Genomic profiling to expand precision cancer medicine in the real world The ROME trial (Video MP4 Format)
Mini Oral session 70MO – Genomic profiling to expand precision cancer medicine in the real world The ROME trial (PDF Format)
Mini Oral session 79MO – Developing international consensus-driven SPIRIT and CONSORT extensions for early phase dose-finding clinical trials (Video MP4 Format)
Mini Oral session 79MO – Developing international consensus-driven SPIRIT and CONSORT extensions for early phase dose-finding clinical trials (PDF Format)
Mini Oral session 80MO – Optimising participant flow diagrams for phase I clinical trials (Video MP4 Format)
Mini Oral session 80MO – Optimising participant flow diagrams for phase I clinical trials (PDF Format)
Mini Oral session Invited Discussant (Video MP4 Format)
Mini Oral session Invited Discussant (PDF Format)
Mini Oral session Oncology phase I trial design and conduct Time for a change – MDICT Guidelines 2022 (Video MP4 Format)
Mini Oral session Oncology phase I trial design and conduct Time for a change – MDICT Guidelines 2022 (PDF Format)
Mini Oral session Panel discussion (Video MP4 Format)
Next-generation macro-molecules Biomarkers to predict response to ADCs (Video MP4 Format)
Next-generation macro-molecules Biomarkers to predict response to ADCs (PDF Format)
Next-generation macro-molecules Human costimulatory bispecific antibodies in cancer immunotherapy (Video MP4 Format)
Next-generation macro-molecules Human costimulatory bispecific antibodies in cancer immunotherapy (PDF Format)
Next-generation macro-molecules Q&A (Video MP4 Format)
Next-generation macro-molecules Radioligand therapy across disease Challenges and opportunities (Video MP4 Format)
Next-generation macro-molecules Radioligand therapy across disease Challenges and opportunities (PDF Format)
Novel kinase inhibitors BRAF inhibitors Targeting class II III alterations (Video MP4 Format)
Novel kinase inhibitors BRAF inhibitors Targeting class II III alterations (PDF Format)
Novel kinase inhibitors EGFR and or HER20 exon 20 inhibitors (Video MP4 Format)
Novel kinase inhibitors EGFR and or HER20 exon 20 inhibitors (PDF Format)
Novel kinase inhibitors KRAS inhibitors beyond G12C (Video MP4 Format)
Novel kinase inhibitors KRAS inhibitors beyond G12C (PDF Format)
Novel kinase inhibitors Q&A (Video MP4 Format)
Novel kinase inhibitors The latest on CDK 4 6 in breast cancer (Video MP4 Format)
Novel kinase inhibitors The latest on CDK 4 6 in breast cancer (PDF Format)
Oral immunotherapy JAK inhibitors as IO therapy (Video MP4 Format)
Oral immunotherapy JAK inhibitors as IO therapy (PDF Format)
Oral immunotherapy Oral PDL1 targeting (Video MP4 Format)
Oral immunotherapy Oral PDL1 targeting (PDF Format)
Oral immunotherapy Q&A (Video MP4 Format)
Oral immunotherapy Small molecules to modulate TCR signalling (Video MP4 Format)
Oral immunotherapy Small molecules to modulate TCR signalling (PDF Format)
Phase I trial methodology Advancement of statistical methodology and its practical implementation in phase I trials (Video MP4 Format)
Phase I trial methodology Advancement of statistical methodology and its practical implementation in phase I trials (PDF Format)
Phase I trial methodology Pharmacodynamic endpoints in FIH trials (Video MP4 Format)
Phase I trial methodology Pharmacodynamic endpoints in FIH trials (PDF Format)
Phase I trial methodology Q&A (Video MP4 Format)
Pre-clinical models and schedule testing Credentialing biomarkers for patient selection (Video MP4 Format)
Pre-clinical models and schedule testing Credentialing biomarkers for patient selection (PDF Format)
Pre-clinical models and schedule testing Preclinical modelling to support contemporary drug development (Video MP4 Format)
Pre-clinical models and schedule testing Preclinical modelling to support contemporary drug development (PDF Format)
Pre-clinical models and schedule testing Q&A (Video MP4 Format)
Predictive and pharmacodynamic biomarkers Biomarker role and potential of single-cell and spatially resolved multiparametric analysis (Video MP4 Format)
Predictive and pharmacodynamic biomarkers Biomarker role and potential of single-cell and spatially resolved multiparametric analysis (PDF Format)
Predictive and pharmacodynamic biomarkers Q&A (Video MP4 Format)
Predictive and pharmacodynamic biomarkers Serum IL-8 as a predictive and pharmacodynamic circulating biomarker in cancer immunotherapy (Video MP4 Format)
Predictive and pharmacodynamic biomarkers Serum IL-8 as a predictive and pharmacodynamic circulating biomarker in cancer immunotherapy (PDF Format)
Predictive and pharmacodynamic biomarkers Tumour microenvironment heterogeneity How to interpret as a biomarker (Video MP4 Format)
Predictive and pharmacodynamic biomarkers Tumour microenvironment heterogeneity How to interpret as a biomarker (PDF Format)
Proffered Paper session 109O – Phase I study of MEDI9253, a recombinant Newcastle Disease Virus encoding interleukin-12 (Video MP4 Format)
Proffered Paper session 109O – Phase I study of MEDI9253, a recombinant Newcastle Disease Virus encoding interleukin-12 (PDF Format)
Proffered Paper session 1O – Safety, pharmacokinetics, efficacy, and biomarker results of SRK-181 (a latent TGFá1 inhibitor) from a phase I trial (DRAGON trial) (Video MP4 Format)
Proffered Paper session 1O – Safety, pharmacokinetics, efficacy, and biomarker results of SRK-181 (a latent TGFá1 inhibitor) from a phase I trial (DRAGON trial) (PDF Format)
Proffered Paper session 27O – First-in-class first-in-human phase I trial of RBN-2397 in patients with advanced solid tumors (Video MP4 Format)
Proffered Paper session 27O – First-in-class first-in-human phase I trial of RBN-2397 in patients with advanced solid tumors (PDF Format)
Proffered Paper session Invited Discussant 1 (Video MP4 Format)
Proffered Paper session Invited Discussant 1 (PDF Format)
Proffered Paper session Invited Discussant 2 (Video MP4 Format)
Proffered Paper session Invited Discussant 2 (PDF Format)
Proffered Paper session Q&A (Video MP4 Format)
Prostate cancer How to manage prostate cancer in 2023 (Video MP4 Format)
Prostate cancer How to manage prostate cancer in 2023 (PDF Format)
Prostate cancer Metabolic radiotherapy-lutetium-PSMA therapy (Video MP4 Format)
Prostate cancer Metabolic radiotherapy-lutetium-PSMA therapy (PDF Format)
Prostate cancer Q&A (Video MP4 Format)
Prostate cancer Tumour genomic profiling What is relevant and how to avoid potential pitfalls (Video MP4 Format)
Prostate cancer Tumour genomic profiling What is relevant and how to avoid potential pitfalls (PDF Format)
Prostate cancer Update on immune checkpoint inhibitors (Video MP4 Format)
Prostate cancer Update on immune checkpoint inhibitors (PDF Format)
Seagen – ADCs’ journey into clinical use – Key considerations for improved outcomes An overview of current approaches utilizing ADCs (Video MP4 Format)
Seagen – ADCs’ journey into clinical use – Key considerations for improved outcomes Introduction (Video MP4 Format)
Seagen – ADCs’ journey into clinical use – Key considerations for improved outcomes Leveraging immune stimulatory ADCs to target immune checkpoints (Video MP4 Format)
Seagen – ADCs’ journey into clinical use – Key considerations for improved outcomes New ADC targets on the horizon (Video MP4 Format)
Seagen – ADCs’ journey into clinical use – Key considerations for improved outcomes Q&A and discussion (Video MP4 Format)
Viral related malignancies Cell-based immunotherapeutic approaches against HPV-associated targets (E7) in HPV-associated advanced cancers (Video MP4 Format)
Viral related malignancies Cell-based immunotherapeutic approaches against HPV-associated targets (E7) in HPV-associated advanced cancers (PDF Format)
Viral related malignancies EBV-targeting and other immunotherapeutic approaches in the treatment of endemic nasopharyngeal carcinoma (Video MP4 Format)
Viral related malignancies EBV-targeting and other immunotherapeutic approaches in the treatment of endemic nasopharyngeal carcinoma (PDF Format)
Viral related malignancies Immunotherapeutic advances in the treatment of advanced virally associated hepatocellular carcinoma (Video MP4 Format)
Viral related malignancies Immunotherapeutic advances in the treatment of advanced virally associated hepatocellular carcinoma (PDF Format)
Viral related malignancies Q&A (Video MP4 Format)
Viral related malignancies Therapeutic vaccines and other non-cell based immunotherapeutic advances against HPV16 E7 and E6 in patients with solid cancers (Video MP4 Format)
Viral related malignancies Therapeutic vaccines and other non-cell based immunotherapeutic advances against HPV16 E7 and E6 in patients with solid cancers (PDF Format)
Welcome to ESMO TAT 2023 and Honorary Award Epigenetic therapies Have they come of age (Video MP4 Format)
Welcome to ESMO TAT 2023 and Honorary Award Epigenetic therapies Have they come of age (PDF Format)
Welcome to ESMO TAT 2023 and Honorary Award Introduction to the 2023 Honorary Award keynote lecture (Video MP4 Format)
Welcome to ESMO TAT 2023 and Honorary Award Introduction to the 2023 Honorary Award keynote lecture (PDF Format)
Welcome to ESMO TAT 2023 and Honorary Award Presentation of 2020-2021-2022 Honorary Awards (Profs. Lillian Siu, Ruth Plummer, Lesley Seymour) (Video MP4 Format)
Welcome to ESMO TAT 2023 and Honorary Award Presentation of 2020-2021-2022 Honorary Awards (Profs. Lillian Siu, Ruth Plummer, Lesley Seymour) (PDF Format)
Welcome to ESMO TAT 2023 and Honorary Award Welcome to ESMO TAT 2023 (Video MP4 Format)
Welcome to ESMO TAT 2023 and Honorary Award Welcome to ESMO TAT 2023 (PDF Format)
Workshop in collaboration with ESMO YOC Data integrity and data sharing Artificial Intelligence How to use technology to obtain the truth (Video MP4 Format)
Workshop in collaboration with ESMO YOC Data integrity and data sharing Artificial Intelligence How to use technology to obtain the truth (PDF Format)
Workshop in collaboration with ESMO YOC Data integrity and data sharing Q&A and discussion (Video MP4 Format)
Workshop in collaboration with ESMO YOC Data integrity and data sharing Research Integrity Does our system of peer-review and academic success contribute (Video MP4 Format)
Workshop in collaboration with ESMO YOC Data integrity and data sharing Research Integrity Does our system of peer-review and academic success contribute (PDF Format)
Workshop in collaboration with ESMO YOC Drug repurposing trials International collaboration and data-sharing for rare targets (Video MP4 Format)
Workshop in collaboration with ESMO YOC Drug repurposing trials International collaboration and data-sharing for rare targets (PDF Format)
Workshop in collaboration with ESMO YOC Drug repurposing trials Q&A and discussion (Video MP4 Format)
Workshop in collaboration with ESMO YOC Drug repurposing trials Why is this important Trials versus off-label use (Video MP4 Format)
Workshop in collaboration with ESMO YOC Drug repurposing trials Why is this important Trials versus off-label use (PDF Format)
Workshop in collaboration with ESMO YOC How to bring new molecular entities to earlier stages of cancer Mermaid 1 & 2 design (Video MP4 Format)
Workshop in collaboration with ESMO YOC How to bring new molecular entities to earlier stages of cancer Mermaid 1 & 2 design (PDF Format)
Workshop in collaboration with ESMO YOC How to bring new molecular entities to earlier stages of cancer Peri-operative endpoints (Video MP4 Format)
Workshop in collaboration with ESMO YOC How to bring new molecular entities to earlier stages of cancer Peri-operative endpoints (PDF Format)
Workshop in collaboration with ESMO YOC How to bring new molecular entities to earlier stages of cancer Q&A and discussion (Video MP4 Format)
Workshop in collaboration with ESMO YOC Phase I design in the era of Project Optimus Importance, background (Video MP4 Format)
Workshop in collaboration with ESMO YOC Phase I design in the era of Project Optimus Importance, background (PDF Format)
Workshop in collaboration with ESMO YOC Phase I design in the era of Project Optimus Practical recommendations (Video MP4 Format)
Workshop in collaboration with ESMO YOC Phase I design in the era of Project Optimus Practical recommendations (PDF Format)
Workshop in collaboration with ESMO YOC Phase I design in the era of Project Optimus Q&A and discussion (Video MP4 Format)
Workshop in collaboration with ESMO YOC- Selecting patients with molecular imaging for anticancer treatment Q&A and discussion (Video MP4 Format)
Workshop in collaboration with ESMO YOC- Selecting patients with molecular imaging for anticancer treatment Selecting patients with molecular imaging for cancer (Video MP4 Format)
Workshop in collaboration with ESMO YOC- Selecting patients with molecular imaging for anticancer treatment Selecting patients with molecular imaging for cancer (PDF Format)